Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01501981
Other study ID # 20120211
Secondary ID
Status Completed
Phase N/A
First received March 30, 2011
Last updated July 22, 2017
Start date February 2011
Est. completion date June 2014

Study information

Verified date July 2017
Source Charite University, Berlin, Germany
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

In this pilot, investigator-initiated multi-centre, multinational, observational study the investigators would like to examine the impact of therapy optimization on the level of biomarkers in patients with acute decompensated and decompensated chronic heart failure.

The primary objective is to determine the best time point for measuring biomarker levels during therapy optimization in patients with decompensation to predict clinical outcomes such as mortality, hospitalisation, and quality of life.

Secondary objectives are:

1. To evaluate the impact of guideline-recommended medication on biomarker levels during and following recompensation.

2. To evaluate whether the trajectory of relevant biomarkers (MR-proANP, MR-proADM) is of relevance to guide medical therapy following decompensation.

3. To evaluate whether the degree of biomarker change (e.g. slow versus rapid change) is of relevance with regard to hemodynamic stability and cardiovascular events such as hospitalisation.

4. To evaluate whether the trajectory of relevant biomarkers (copeptin, CT-pro-ET1) is of relevance to guide medical therapy following decompensation.


Recruitment information / eligibility

Status Completed
Enrollment 150
Est. completion date June 2014
Est. primary completion date December 2013
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Male or female patients = 18 years.

2. Hospitalized for ADHF or decompensated chronic heart failure. Patients who develop ADHF while hospitalized for another reason are not eligible.

3. The underlying primary etiology for decompensation should be cardiac rather than pulmonary disease. For this study, all of the following must be observable at the time of screening:

- Dyspnea at rest (sitting or supine) or with minimal exertion (such as talking, eating, etc.) - NYHA III/IV;

- Pulmonary congestion on physical examination or chest x-ray;

4. Able to begin study within 24 hours from presentation to the hospital, including time spent in the emergency department.

5. Be adequately informed of the nature and risks of the study and give written informed consent prior to study start.

Exclusion Criteria:

1. Acute or suspected acute myocardial infarction (AMI) or troponin levels > 3x the upper limit of normal. at the institution's local laboratory.

2. Cardiogenic shock.

3. Temperature > 38°C (oral or equivalent), sepsis or active infection requiring IV antimicrobial treatment.

4. ADHF due to significant arrhythmias (ventricular tachycardia, bradyarrhythmias with ventricular rate < 45 bpm or atrial fibrillation/flutter with ventricular response of > 150 bpm).

5. Current or planned ultrafiltration, hemofiltration, or dialysis.

6. Significant pulmonary disease (history of oral daily steroid dependency, history of CO2 retention or need for intubation for acute exacerbation, or currently receiving IV steroids), or thoracic cage injury which compromises breathing.

7. Any organ transplant recipient or patients currently listed or admitted for transplantation.

8. Acute myocarditis or hypertrophic obstructive, restrictive, or constrictive cardiomyopathy (not including restrictive mitral valve filling patterns).

9. Women who are pregnant or breastfeeding.

10. Malignant disease with a life expectancy of less than two years.

11. Autoimmune disease.

12. Any condition or treatment of a condition which, in the opinion of the investigator, could interfere with the conduct of the study, or which would unacceptably increase the risk of the patient's participation in the study. This may include, but is not limited to, alcoholism, drug dependency or abuse, other severe mental disorders, epilepsy, or any unexplained episodes of syncope.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Germany Charité Campus Virchow Klinikum-Medizinische Klinik mit Schwerpunkt Kardiologie Berlin

Sponsors (2)

Lead Sponsor Collaborator
Charite University, Berlin, Germany Brahms AG

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Time to first event - all cause death - cardiovascular death - all cause hospitalisation - cardiovascular hospitalisation - hospitalization for heart failure Time to first event
all cause death
cardiovascular death
all cause hospitalisation
cardiovascular hospitalisation
hospitalization for heart failure
from study start (day 1) during hosptialisation until second year of follow up
Secondary quality of life The EuroQoL EQ-5D quality of life scale consists of 5 items scaled 1 to 3 reflecting different dimensions of quality of life and a visual analog scale measuring overall self-rated health.
The Short Form 36 Health Survey. The Hospital Anxiety and Depression Scale (HADS) consists of 14 items measuring symptoms of anxiety and depression in physically ill patients.
The ENRICHD Social Support Instrument (ESSI) has been developed as a brief tool for measuring perceived social support in the large randomized ENRICHD study.
from study start (day 1) during hosptialisation until second year of follow up
Secondary Six-minute walk test distance Six-minute walk test distance will be performed at Visit 1-6 a s well as Follow-up after first and second year. from study start (day 1) during hosptialisation until second year of follow up
Secondary Echocardiographic parameters Echocardiography (done within the first seven days from the day of entering the study): dimensions of the left ventricle, wall thickness and EF per Simpson (if it is not possible to determine EF per Simpson in particular cases due to very limited sound conditions, then it could be visually assessed by an experienced echocardiographer), diastolic function of the left ventricle per the American Society of Echocardiography (ASE): mitral Doppler, tissue Doppler, pulmonary vein Doppler. from study start (day 1) during hosptialisation until second year of follow up
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05910437 - Optimizing Treatments for Heart Failure During Hospitalization
Terminated NCT00355017 - BNP Guided Care in Addition to Multidisciplinary Care N/A
Active, not recruiting NCT03701880 - Early Use of Ivabradine in Heart Failure N/A
Recruiting NCT03157219 - Manipal Heart Failure Registry (MHFR) N/A
Recruiting NCT06114498 - Hospital Register of Decompensated Heart Failure With Preserved Ejection Fraction
Completed NCT03838003 - Exercise in Patients Admitted With Recently Decompensated Heart Failure N/A
Completed NCT02997462 - Monocyte Phenotypic Changes in Heart Failure
Completed NCT04493346 - Shear Wave Elastography
Recruiting NCT02666651 - Regional Tolvaptan Registry Phase 4
Recruiting NCT02236247 - Control of Sinus Node Tachycardia as an Additional Therapy in Patients With Decompensated Heart Failure Phase 1/Phase 2
Not yet recruiting NCT06273397 - Acetazolamide or Metolazone in Acute Heart Failure N/A
Completed NCT05927285 - Effect on Kidney Function Recovery Guiding Decongestion With VExUS in Patients With Cardiorenal Syndrome 1 N/A
Withdrawn NCT04572867 - Aquapheresis Efficacy in Outpatients With Decompensated Heart Failure N/A
Completed NCT02157506 - A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure Phase 2
Recruiting NCT03914222 - Comparing PA Compliance During and After Decompensation in HFP N/A
Recruiting NCT06286423 - Colchicine in Acutely Decompensated HFREF Phase 4
Recruiting NCT03009552 - Speckle Tracking Echocardiography Adds Information in Decompensated Heart Failure N/A
Completed NCT04019314 - Assessment of ProEnkephalin to Detect Acute Kidney Injury (AKI) N/A
Recruiting NCT02649517 - Clinical and Morphological Characteristics of Chronic Inflammation in the Myocardium in Patients With Decompensated HF With Ischemic Systolic Dysfunction N/A
Recruiting NCT03440970 - Mechanism and Effects of Manipulating Chloride Homeostasis in Stable Heart Failure Early Phase 1